Evidence map›Paper›PMID 42879027›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Ewing Sarcoma PDX Models.

Didier Surdez, Lorena Landuzzi, Katia Scotlandi, Maria Cristina Manara

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Didier SurdezBalgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland.
Lorena LanduzziIRCCS- Istituto Ortopedico Rizzoli, Laboratory of Oncology Research and Functional Genomics (ONCOGEN), Bologna, Italy.
Katia ScotlandiIRCCS- Istituto Ortopedico Rizzoli, Laboratory of Oncology Research and Functional Genomics (ONCOGEN), Bologna, Italy.
Maria Cristina ManaraIRCCS- Istituto Ortopedico Rizzoli, Laboratory of Oncology Research and Functional Genomics (ONCOGEN), Bologna, Italy. mariacristina.manara@ior.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing sarcoma (EWS) is a rare malignant pediatric tumor, and patient-derived xenografts (PDXs) could represent a possibility to increase the number of available models to study this disease. Compared to cell-derived xenografts (CDX), PDXs are reported to recapitulate better tumor microenvironment, heterogeneity, genetic, and epigenetic features. They are considered reliable models due to their superior predictive value when comparing preclinical efficacy and treatment response in patients. In this chapter, we extensively describe a method for generating EWS PDX models, along with their validation and molecular characterization.

Indexed as

Bone NeoplasmsSarcoma, EwingXenograft Model Antitumor AssaysAnimalsCell Line, TumorDisease Models, AnimalHeterograftsHumansMiceMice, SCIDTumor MicroenvironmentEwing sarcomaImmunodeficient micePatient-derived xenograft cell linesPatient-derived xenograftsPediatric tumorsPreclinical models

Identifiers

PMID42879027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.